# A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.

> **NCT00752505** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 89 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** Esreboxetine
- **DRUG:** Esreboxetine

## Key facts

- **NCT ID:** NCT00752505
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2018-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752505, "A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00752505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*